Australia's most trusted
source of pharma news
Posted 24 November 2021 PM
Eli Lilly has taken Novo Nordisk to Medicines Australia over an alleged breach of the Code of Conduct for failing to "act promptly" to correct news articles that promoted the off-label use of Ozempic for weight loss/weight management in the mainstream media.
But according to an MA complaint outcome report, the claim was dismissed after investigation, with a finding that there was no breach of the code.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.